Golgi Protein for HCC Diagnosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-12-22

Study Completion Date

2015-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This case-control study was conducted on 90 patients who were equally divided into two groups. Group 1 included 45 patients with HCV-related chronic liver disease without clinical or radiological evidence of HCC (control group), and Group 2 included 45 patients diagnosed to have HCC by Triphasic abdominal CT (patient group). Serum AFP and GP73 were measured using ELISA technique

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Case-Control Study of the Glycotest™ HCC Panel Vs AFP for the Detection of Early-stage Hepatocellular Carcinoma

NCT03878550

Carcinoma, Hepatocellular Cirrhosis, Liver

ACTIVE_NOT_RECRUITING

Diagnostic Accuracy of APAC, ASAP and GALAD Scores in Hepatocellular Carcinoma Among Cirrhotic Patients

NCT05738772

Hepatocellular Carcinoma

UNKNOWN

The Assesment of MMP-1 Genotypes Polymorphism as a Risk Factor for HCC in Chronic HCV Patients With LC

NCT03722628

Hepatocellular Carcinoma

UNKNOWN

A Clinical Study of GP73 as a Hepatocellular Carcinoma (HCC) Tumor Mark

NCT00902902

Hepatocellular Carcinoma

UNKNOWN

Risk of Hepatocellular Carcinoma in Patient With Liver Cirrhosis

NCT03083002

Carcinoma, Hepatocellular

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Screening for Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HCC

Serum Golgi Protein 73

Intervention Type DIAGNOSTIC_TEST

Serum test

liver cirrhosis No HCC

Serum Golgi Protein 73

Intervention Type DIAGNOSTIC_TEST

Serum test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Serum Golgi Protein 73

Serum test

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients were older than 18 years.

Exclusion Criteria

* patients with hepatic focal lesions not due to HCC such as Hemangioma, Hepatic cyst, and liver metastases; patients infected with HIV; patients with any autoimmune disease; or patients with metastatic disease.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No